Home > News > The New Global Player in Ophthalmology Croma-Pharma Acquires Cornéal® Laboratories and Xcelens
Corneal Disorders
Read Time: 3 mins

The New Global Player in Ophthalmology Croma-Pharma Acquires Cornéal® Laboratories and Xcelens

Published Online: January 26th 2011 European Ophthalmic Review,2007:1-2 DOI: http://doi.org/10.17925/EOR.2007.00.00.1b
Authors: Croma-Pharma
Quick Links:
Article
Article Information
Article:

Founded in 1976, Croma-Pharma has become a specialist in the field of research, development and production of viscoelastic fluids as well as the sale of high-quality ophthalmic products. Right from the start, Croma- Pharma established itself as a strong and reliable partner for both ophthalmologists and patients.


Founded in 1976, Croma-Pharma has become a specialist in the field of research, development and production of viscoelastic fluids as well as the sale of high-quality ophthalmic products. Right from the start, Croma- Pharma established itself as a strong and reliable partner for both ophthalmologists and patients.

Today, Croma-Pharma is successfully managed by Martin Prinz (Managing Director (MD) of Research and Development (R&D) and Manufacturing) and Andreas Prinz (MD of Marketing and Sales). This year Croma-Pharma finally ensured its long-term success by acquiring two leading providers in cataract surgery – Cornéal® Laboratoires’ ophthalmic business unit (June 2007) and Xcelens® (July 2007).

Croma-Pharma became one of the most important one-stop providers of ophthalmic products in Europe. It offers products for both anterior and posterior segment surgery and focuses mainly on viscoelastic fluids, intraocular lenses (IOLs), medical devices and instruments.

Croma-Pharma currently ranks among the top five companies on the ophthalmic market with eight subsidiaries in Europe including 400 highly skilled employees. In addition, a worldwide net of distributors successfully co-operates with Croma-Pharma. Nevertheless, the company continues to be 100% privately owned.

Croma-Pharma manufactures all of its viscoelastic fluids and intraocular lenses exclusively in its own production facilities. Careful selection of high-quality raw materials and a manufacturing procedure that follows strict safety requirements and validated Good Manufacturing Practices (GMP) and International Organisation for Standardisation (ISO) guidelines guarantee constant premium quality and highest safety for both doctors and patients. In addition to these activities, Croma-Pharma’s research teams are constantly looking for new and innovative solutions.

The New Portfolio

Viscoelastic Fluids
Viscoelastic fluids are indispensable devices for each cataract surgery. Currently, Croma-Pharma is developing a completely new range of viscoelastic fluids that includes four innovative products:

• Eyefill H.D.
• Eyefill D.C.
• Eyefill S.C.
• Eyefill H.C.

These will be available soon. Due to the high level of safety and quality mentioned above, Croma-Pharma’s viscoelastic fluids offer everything that is needed during cataract surgery, e. g. perfect protection of the vulnerable endothelial tissue, outstanding stabilisation of the anterior chamber and the capsular bag and best possible tolerability.

Eyefill S.C.
• 2% biofermentative hyaluronic acid
• molecular weight: 3.106 Dalton
• viscosity (0.1s-1): 400,000 mPa·s
• volume: 0.9ml
• inner and outer sterility guaranteed

Eyefill S.C. is a viscous cohesive viscoelastic fluid and is indicated for standard cataract surgeries. It features comfortable retention in the anterior chamber during phacoemulsification, easy removal at the end of the surgery and guarantees remarkable protection of the intraocular tissue.

Intraocular lenses
As far as IOL are concerned, Croma-Pharma currently focuses on hydrophilic acrylic lenses, which undoubtedly feature numerous advantages, e.g. excellent biocompatibility, better vision quality and supreme contrast sensitivity, as recent studies have shown.1 ,2 Quatrix® Aspheric Pre-loaded

• pre-loaded IOL in a single-use injector
• designed to fit all capsular bag diameters
• one-piece
• hydrophilic acrylic
• optic diameter: 6mm
• optic profile: square edge (over 360°)
• overall diameter: 11mm
• implantation: capsular bag
• A constant: 119.6 (SRK II / US biometry)
• theoretical ACD: 5.90mm
• angulation: 6°
• incision size: 2.8mm
• available: from +10D to +30D (increment by 0.5D)
• steam sterilisation

Quartrix® aspheric features four haptics for an excellent centration and eight supports for a large contact zone to prevent capsular folds. Its aspheric optic guarantees superior contrast sensitivity. The pre-loaded injector system guarantees easy and safe folding and protects the lens against damage.

Article Information:
Received

2011-01-26T00:00:00

References

  1. Dr M Assouline, September 2001,
  2. Akman A, Bozbeyoglu S, Akova YA, Glare disability in patients with hydrophilic and hydrophobic acrylic intraocular lens implants. Eur J Ophthalmol. 2004,14(1):14–8.

Further Resources

Share this Article
Related Content In Corneal Disorders
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72